Navigation Links
Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib
Date:12/27/2011

double-blind, placebo-controlled, multiple-dose escalating trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamic effect of NSI-189 in the treatment of MDD. Phase Ia tested escalating doses of single administration of NSI-189 in healthy patients. Phase Ib will test the safety of escalating doses of NSI-189 for 28 daily administrations in 24 depressed patients. The Phase Ib portion of the trial is expected to take approximately six months to complete.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depressive disorder (MDD).  Additional indications co
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neuralstem Updates NSI-189 Major Depression Trial
2. Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
10. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Decision Resources Group ... of the U.S. Food and Drug Administration,s (FDA) approval ... binder Velphoro, which was approved by the FDA in ... kidney disease (CKD) patients on dialysis. Other ... Nephrology (US) Q2 2014 : ...
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ... Consumables Market - Global Industry Analysis, Size, Share, Growth, ... their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... are used on patients in order to treat dental ...
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... Ore. and NEPTUNE, N.J., Jan. 11, 2012 /PRNewswire-iReach/ ... patients to easily record their pain levels before and ... available, useful, patient information.  The Health Journal for Pain ... stamp pain levels and the impact of both long-acting ...
...  MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, ... and bioimplants processed from human amniotic membrane, announced ... Capital Markets 8th Annual Equity Conference in Hollywood, ... William C. Taylor, President and COO and Michael ...
Cached Medicine Technology:HealthSaaS Inc. with iMPak Health and Meridian Health Announce Integrated Pain Management and Medication Adherence Solution 2HealthSaaS Inc. with iMPak Health and Meridian Health Announce Integrated Pain Management and Medication Adherence Solution 3
(Date:7/11/2014)... July 11, 2014 Operators ... $50 billion in fuel costs now that ... current GHG standards are phasing ... it upon themselves to install new features ... 1.    Idle reduction technologies , 2.    Efficient driveline components ...
(Date:7/11/2014)... 11, 2014 The report “Probiotics ... Nutrients, Animal Feed), Applications (Regular, Therapeutic, Preventive Health ... Trends & Forecasts to 2019 ” defines and ... and forecasting of the market value of probiotic ... driving and restraining factors for the global market ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Presently, disposable ... overall healthcare equipment and supplies segment. During the past ... witnessed steady growth (on an average 12.5% per year), ... healthcare settings. Currently, the US is the largest market ... a share of 40%. The second position is held ...
(Date:7/11/2014)... NY (PRWEB) July 11, 2014 The ... the five years to 2014 on the heels of ... 2010 prompted farmers to dedicate a larger share of ... production. More specifically, the regulations required the mixing of ... expanding biofuel production in the United States created a ...
(Date:7/11/2014)... Ticket Down is a reliable source ... Amphitheatre in Wheatland, CA. In the Sacramento California ... the Sleep Train Amphitheatre can do for music fans. The ... the course of its existence and can seat 18,500 fans ... Wheatland (Sacramento metro area) will host the “That’s My Kind ...
Breaking Medicine News(10 mins):Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3
... live with diabetes across the world and 4.4 million ... control can lead to devastating complications, like blood vessel ... cause 85% of all amputations. , The Faculty of ... of Rotary International has just received a grant for ...
... and medical staff can now be on the same ... EnglishSpanish (Una Gua Para el Paciente Sobre Procedimientos de ... Written in both English and Spanish, the book explains ... the patient can expect prior to and during more ...
... Baxa Corporation announces,the latest addition to its ... offerings. Safe Handling and Preparation of Hazardous ... physicians that prepare,handle or administer hazardous drugs. ... compliance and industry best practice to provide,the ...
... Angiography plus anti-clotting drug keep tissue viable, researchers say ... treatment can help save severely frostbitten limbs that might ... severe frostbite, deep tissue freezing can damage muscles, tendons, ... limb amputation, according to background information in the study. ...
... 24, 2008 -- Share ... name change to Hill-Rom Holdings, Inc., at separation; recently created Batesville ... and "When Issued" Trading expected to commence March ... 19, 2008, ...
... RALEIGH, N.C., March 17 Randy Jackson, music ... to help raise awareness,among the local community about ... (CVD). Jackson partnered with the American Heart,Association to ... Heart of,Diabetes(TM), to help those living with type ...
Cached Medicine News:Health News:Egyptian foot care center recieves International Diabetes Federation grant 2Health News:Flip-chart book translates complicated medical procedures into easy-to-understand language 2Health News:Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility 2Health News:Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility 3Health News:Therapy Could Save Limbs After Frostbite 2Health News:Hillenbrand Industries Announces Formal Board Approval of Separation by Means of Share Distribution and Details for Completion 2Health News:Hillenbrand Industries Announces Formal Board Approval of Separation by Means of Share Distribution and Details for Completion 3Health News:Hillenbrand Industries Announces Formal Board Approval of Separation by Means of Share Distribution and Details for Completion 4Health News:Randy Jackson and the American Heart Association Educate Raleigh Area Residents About the Connection Between Type 2 Diabetes and Cardiovascular Disease 2Health News:Randy Jackson and the American Heart Association Educate Raleigh Area Residents About the Connection Between Type 2 Diabetes and Cardiovascular Disease 3
... especially suited for cell analysis and ... allows to analyze scatter signals in ... channels. Data acquisition, analysis, and real-time ... PC employing Partec DPAC software, built-in ...
Dual laser powered flow cytometer...
... The IMMULITE 2000, a continuous ... throughput of 200 tests per hour, ... efficiency and consolidation in medium- and ... package, with its self-explanatory graphical user ...
... Vidas is an automated, ... designed testing device stores the ... thus optimizing the cost-per-patient result. ... minimum maintenance, ease of use ...
Medicine Products: